33 results about "Plasma mhpg" patented technology

The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta / delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-M, apolipoprotein E, C4b-binding protein beta chain, intact / cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase / arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein.

A system and method for providing a therapeutic plasma protein dosing regimen includes determining a patient's pharmacokinetic profile using a Bayesian model of the sampled patient's pharmacokinetic profile. The example systems and methods also include determining a first dosing regimen for a first prescribed dosing interval comprising (i) a first dose and (ii) the patient over a period of time based at least on the pharmacokinetic profile. and determining a second dosing regimen for a second prescribed dosing interval comprising (i) a second dose and (ii) at least based on said pharmacokinetic profile over said time The second therapeutic plasma protein level in the patient described in paragraph. The example systems and methods further include displaying the first dosing regimen and the second dosing regimen on a client device such that the first dosing regimen is displayed in conjunction with the second dosing regimen.

The invention discloses a sample pre-treatment device for determining nano-grade cerium oxide in blood plasma or blood serum by adopting an inductively coupled plasma mass spectrometer. The sample pre-treatment device comprises the following steps: step 1, uniformly distributing nano-grade cerium oxide particles; step 2, adding a reduction agent into the nano-grade cerium oxide particles; step 3, digesting blood plasma protein or blood serum protein and carrying out reduction treatment on the cerium oxide particles; step 4, carrying out post-treatment. According to the sample pre-treatment device disclosed by the invention, a stock and working solution is prepared by adopting a mixed solution of nitric acid and Triton-X-100 and the nano-grade cerium oxide particles stably exist in the solution; a manner of digesting in a water bath at 80 DEG C for one night is adopted and the blood plasma protein or the blood serum protein is digested to reduce cerium oxide into trivalent cerium ions, so that accurate detection of an inductively coupled plasma mass spectrum can be carried out. According to the sample pre-treatment device disclosed by the invention, a nano-grade cerium oxide particle solution is stable and the protein is completely digested; a method is simple to operate and the testing cost is low; the determination of a large batch of blood plasma samples can be realized in one step.

A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively. Addition of N-acetyl cysteine after heat treatment and optionally before heat treatment maintains a low level of met-hemoglobin. The heat stable cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer.The inventive tetrameric hemoglobin can also be used to prevent tumor metastasis and recurrence following surgical tumor excision. Further the inventive tetrameric hemoglobin can be administered to patients prior to chemotherapy and radiation treatment.

The invention discloses a full-automatic plasma processing equipment and method. The equipment comprises a pH pump, an acetic acid pump, an ethanol pump, a plasma pump, a plasma precipitation reaction pool, a buffer solution circulating pump, a buffer solution trap, a buffer solution tank, a three-way valve and a feedback control system; the pH pump, the acetic acid pump and the ethanol pump are communicated with the buffer solution trap and the buffer solution tank respectively through a first mixer, the feedback control system is arranged between the buffer solution trap and the buffer solution tank, and the feedback control system is electrically connected with the pH pump, the acetic acid pump and the ethanol pump; the first port of the three-way valve is communicated with the buffer solution tank, the second port of the three-way valve is communicated with the plasma precipitation reaction pool, the third port of the three-way valve is communicated with the buffer solution circulating pump, and the buffer solution circulating pump and the plasma pump are communicated with the buffer solution tank through a second mixer. Accordingly, full automation can be achieved, the conductivity, ethanol concentration and acidity and alkalinity of a buffer solution are accurately controlled, protein in the plasma is precipitated through online verification, the recovery rate and yield of the plasma protein can be increased, and profit rate is increased.

The invention relates to the technical field of medical biological detection, and provides a plasma protein marker for predicting the risk of acute mountain sickness and the application of the plasma protein marker in preparing a diagnostic reagent or a diagnostic kit for susceptibility to acute mountain sickness. The plasma protein marker of the present invention is a combination of plasma proteins ACADL, ACADM, ASS1, ATP11C, CANX, DDX3X, HMGB1, HSP90AA1, PSMC2 and RAN. The present invention further provides a kit and a detection method utilizing the susceptibility diagnosis of acute mountain sickness. The kit and detection method of the present invention are simple, reliable, short in cycle, high in specificity, and easy for clinical promotion.